Covid symptom study, another day, another record number of cases

https://covid.joinzoe.com/data

ONS latest

https://www.ons.gov.uk/peoplep....opulationandcommunit

7.56% in England (1 in 13 people)

6.97% in Wales (1 in 14 people)

6.70% in Northern Ireland (1 in 15 people)

8.57% in Scotland (1 in 12 people)

Reinfection

The risk of reinfection was around 10 times higher in the period when the Omicron variant was most common (20 December 2021 to 20 March 2022),

compared with the period when the Delta variant was most common (17 May to 19 December 2021).
UK official data

https://coronavirus.data.gov.uk

REACT – 1 Round 19 (final round)

https://www.imperial.ac.uk/med....icine/research-and-i

https://spiral.imperial.ac.uk/....bitstream/10044/1/96

Community infection trends

RESULTS

In March 2022, prevalence was 6.37% (N=109,181),

more than twice that in February 2022
Lineages determined by viral genome sequencing

3,382 (99.97%) were Omicron,

346 (10.2%) BA.1, 3035 (89.7%) BA.2

one (0.03%) BA.3 sub-lineage

one (0.03%) was Delta AY.4

BA.2 Omicron sub-lineage had a growth rate advantage (compared to BA.1 and sub-lineages) of 0.11

Overall R=1.07

greatest increase in those aged 55+ years (R=1.12)

prevalence (in over 55s) on March 31, 2022 was 8.31%,

nearly 20-fold the median prevalence since May 1, 2020.

CONCLUSIONS
unprecedented levels of SARS-CoV-2 infection in England in March 2022

almost complete replacement of Omicron BA.1 by BA.2.

The high and increasing prevalence in older adults may increase hospitalizations and deaths,

despite high levels of vaccination.

(Funded by the Department of Health and Social Care in England.)

US data

https://covid.cdc.gov/covid-da....ta-tracker/#cases_to

Antibody Seroprevalence

https://covid.cdc.gov/covid-da....ta-tracker/#antibody

Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories

43.3%

These percentages do not include people who have been vaccinated

and have no history of infection.

i.e. includes those vaccinated with a history of infection

Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations)

Combined seroprevalence
94.7%

Infection induced seroprevalence
28.8%